Sanofi said on Oct. 6 that the French healthcare company had found positive results from the first study into a high-dose influenza vaccine with a Covid-19 mRNA booster.
Pfizer Inc. announced Sept. 27 that the first participants were dosed in a Phase 1 clinical trial to evaluate the safety, tolerability, and immunogenicity of a single-dose quadrivalent mRNA vaccine against influenza in healthy adults.
Vaccine developer Novavax Inc. said on Sept. 8 the company initiated an early-stage study to test a combination of the flu shot NanoFlu and the Covid-19 vaccine NVX-CoV2373.
The first human case of a new strain of avian flu was diagnosed in China in late May. Chinese health authorities say there is a low risk of contagion. After China notoriously underreported COVID-19 mortality, can this new assurance be trusted?
With Lyme disease season emerging and the Covid-19 pandemic still with us, an important webinar designed to help physicians differentiate between the two (as well as the flu) so as to provide timely diagnosis and treatment for their patients will be held on Wednesday, May 5. The webinar is the latest in an ongoing series sponsored by Quidel, the California-based diagnostic health care manufacturer known for successfully developing rapid diagnostic health solutions.
Cidara Therapeutics inked a deal worth up to $780 million with Johnson & Johnson to develop and commercialize Cidara’s candidate CD388 for the prevention and treatment of seasonal and pandemic influenza.
Genetic testing specialist Qiagen received emergency use authorization for a new coronavirus test from the U.S. drugs regulator.
A recent study published in Science Translational Medicine shows that a new flu vaccine appears to protect monkeys against influenza strains that are likely to cause a global pandemic, giving researchers hope that this vaccine could hold the key to providing a future universal flu vaccine for humans.
The U.S. health regulator granted emergency use authorization for Abbott Laboratories’ molecular test to detect and distinguish the coronavirus and two types of flu viruses with a single test.
Vir Biotechnology and GlaxoSmithKline expanded a collaboration to develop strategies against COVID-19 to include work into new treatments for influenza and other respiratory viruses.
